Pharmaceutical Care for a Child with Mycoplasma Pneumonia Complicating with Human Immunoglobulin (pH4)for Intravenous Injection Non-sensitive Type Kawasaki Disease
10.6039/j.issn.1001-0408.2015.29.46
- VernacularTitle:1例支原体肺炎并发人丙种球蛋白非敏感型川崎病患儿的药学监护
- Author:
Nianying DENG
;
Chengfu JING
- Publication Type:Journal Article
- Keywords:
Pharmaceutical care;
Clinical pharmacists;
Kawasaki disease;
Mycoplasma pneumonia
- From:
China Pharmacy
2015;(29):4160-4162
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the breakthrough point of clinical pharmacists participating in the treatment for a child with Mycoplasma pneumonia complicating with Kawasaki disease,and standardize pharmaceutical care mode. METHODS:Taking a case of Mycoplasma pneumonia complicating with Kawasaki disease as example,according to the use of antibiotics,human im-munoglobulin (pH4) for intravenous injection,non-steroidal anti-inflammatory drugs (NSAIDS),glucocorticoids,combined with clinical manifestations and disease,whole course pharmaceutical care was conducted,using drug interaction,ADR,precautions, discharge education as breakthrough points. RESULTS:In view of possible ADR,clinical pharmacists adopted combination mea-sures for early prevention,and monitoring measures for early identification and intervention to find problems in time,prevent the occurrence of ADR and improve patient compliance. CONCLUSIONS:What clinical pharmacists carry out pharmaceutical care in the treatment group is beneficial to improve the level of clinical treatment,so as to better safeguard patients’medication safety.
